OLN324 has shown significantly quicker and more substantial enhancements in anatomic results in patients with diabetic macular edema (DME), along with slightly higher visual improvements that were maintained throughout 20 weeks. This was achieved with fewer follow-up treatments when compared to faricimab. Recent anatomical data indicates that OLN324 effectively achieves faster, greater, and longer-lasting improvements in DME patients.